GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MedPacto 235980.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

3,550

+6.29%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About MedPacto

Its shares trade on KOSDAQ under the ticker 235980.KQ. It has been listed since 19 December 2019. In the fiscal year to 31 December 2025, it reported revenue of ₩3.90bn and a net loss of ₩12.81bn. At that date it held total assets of ₩48.66bn and shareholders' equity of ₩45.98bn.

MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
19 Dec 2019
Employees
53

Leadership

Pay as last reported

  • Mr. Seong Jin KimChief Executive Officer, Director
  • Mr. Seon Jeong KimChief Financial Officer, Managing Director
  • Mr. Gi Baek HahmVice President
  • Mr. Dong Yin YookVice President
  • Mr. Seon Jin HwangManaging Director
  • Ms. Jeong Yim HuhAssistant Managing Director
  • Mr. Sae Rom KimAssistant Managing Director
  • Mr. Yeon Sik SongInternal Auditor
  • Mr. Yeong Sik KimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • MedPacto's vactosertib targets multiple myeloma and lung cancer treatments effectively.
  • The company's MA-B2 diagnostic kit aids in early detection of stomach and colon cancer.
  • Seoul-based MedPacto has a focused research team of 53 employees in biotechnology.

Weaknesses

  • MedPacto's limited employee count of 53 may hinder large-scale drug development efforts.
  • The company's reliance on a few key products like vactosertib and MA-B2 poses risks.
  • MedPacto's IPO in 2019 may limit access to substantial capital for expansion.

Opportunities

  • Expanding vactosertib to treat triple negative breast cancer could increase market share.
  • Growing demand for diagnostic kits in Seoul's healthcare sector presents new opportunities.
  • Collaborating with KR's health care providers could enhance product adoption.

Threats

  • Competition from established biotech firms in the KR market may challenge MedPacto.
  • Regulatory changes in the Health Care sector could delay product approvals.
  • Rising costs in the biotechnology industry may impact research budgets significantly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.